She specifically discusses the available treatment options in frontline EGFR mutation–positive advanced non–small cell lung cancer and what particular clinical and lifestyle benefits are provided by ...

Misako Nagasaka, MD, PhD, describes the tolerability results with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced non–small cell lung cancer from ...

Misako Nagasaka, MD, PhD, discusses the overall response rate and duration of response with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced ...

Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated ...

Misako Nagasaka, MD, PhD, discusses optimizing patient management when administering frontline SC amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. She ...

Explore how oncologists battle information overload, navigate conflicting trial data, and weigh AI tools while keeping ...

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...

Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) ...

Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...

NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...